Abstract
Erectile and endothelial dysfunction are common in individuals with multiple cardiovascular risk factors and are longitudinal predictors of cardiovascular events. The pathogenesis of both endothelial and erectile dysfunction is intimately linked through increased expression and activation of endothelial nitric oxide synthase, and the subsequent physiological actions of nitric oxide. Endothelial production of nitric oxide by endothelial nitric oxide synthase in the corpus cavernosum is involved in the maintenance of penile erection. Erectile dysfunction can be detected clinically using systematic questioning and could potentially be employed as an independent predictor of cardiovascular risk to target treatment of cardiovascular risk factors. Both erectile and endothelial dysfunction respond to lifestyle modifications, particularly in individuals with the metabolic syndrome. Drugs that improve endothelial dysfunction can also improve erectile dysfunction, but responses are not always concordant. Phosphodiesterase type 5 inhibitors, however, are powerful agents that commonly improve erectile and endothelial dysfunction, with potential cardiac applications. The recent Princeton consensus requires more extensive implementation and evaluation in clinical practice. The judicious diagnosis of erectile dysfunction, nevertheless, provides a unique opportunity for the prevention of cardiovascular disease.
Key Points
-
Endothelial and erectile dysfunction are intimately associated; both disorders arise from disturbance in the release and action of nitric oxide from endothelial cells
-
Erectile and endothelial dysfunction can be readily detected clinically and are associated with a wide spectrum of cardiovascular risk factors, and are also independently predictive of cardiovascular events
-
Both conditions can be improved by lifestyle modifications and by several pharmacological agents
-
Phosphodiesterase type 5 inhibitors improve both endothelial and erectile dysfunction by potentiating the action of nitric oxide from endothelial cells
-
The Princeton consensus offers practical guidelines for assessing cardiovascular risk in patients with erectile dysfunction and managing erectile dysfunction in patients with established coronary artery disease
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
NIH Consensus Development Panel on Impotence (1993) Impotence. JAMA 270: 83–90
Shabsigh R and Anastasiadis AG (2003) Erectile dysfunction. Annu Rev Med 54: 153–168
Montorsi P et al. (2004) Common grounds for erectile dysfunction and coronary artery disease. Curr Opinion Urol 14: 361–365
Corbin JD et al. Phosphodiesterase-5 inhibitors: importance to the cardiovascular system. In Contemporary Cardiology: Heart Disease and Erectile Dysfunction, 117–137 (Ed Kloner RA) Totowa: Humana Press Inc.
Andersson KE and Wagner G (1995) Physiology of penile erection. Physiol Rev 75: 191–236
Traish AM and Guay AT (2006) Are androgens critical for penile erections in humans? Examining the clinical and preclinical evidence. J Sex Med 3: 382–407
Burnett AL (1997) Nitric oxide in the penis: physiology and pathology. J Urol 157: 320–324
Maas R et al. (2002) The pathophysiology of erectile dysfunction related to endothelial dysfunction and mediators of vascular function. Vasc Med 7: 213–225
Saenz de Tejada I et al. (2004) Physiology of erectile function. J Sex Med 1: 254–265
Hurt KJ et al. (2002) Akt-dependent phosphorylation of endothelial nitric-oxide synthase mediates penile erection. Proc Natl Acad Sci USA 99: 4061–4016
Burnett AL (2004) Novel nitric oxide signaling mechanisms regulate the erectile response. Int J Impot Res 16: S15–S19
Solomon H et al. (2003) Erectile dysfunction and the cardiovascular patient: endothelial dysfunction is the common denominator. Heart 89: 251–253
Bortolotti A et al. (1997) The epidemiology of erectile dysfunction and its risk factors. Int J Androl 20: 323–334
Bonetti PO et al. (2003) Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 23: 168–175
Cooke JP and Dzau VJ (1997) Nitric oxide synthase: role in the genesis of vascular disease. Annu Rev Med 48: 489–509
Celermajer DS et al. (1994) Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol 24: 1468–1474
Brunner H et al. (2005) Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens 23: 233–246
Farouque HMO and Meredith IT (2001) The assessment of endothelial function in humans. Coron Artery Dis 12: 445–454
Vita JA and Keaney JF Jr (2002) Endothelial function: a barometer for cardiovascular risk? Circulation 106: 640–642
Lyons D et al. (1997) Impaired nitric oxide-mediated vasodilatation and total body nitric oxide production in healthy old age. Clin Sci (Lond) 93: 519–525
Cooke JP (2005) ADMA: its role in vascular disease. Vasc Med 10 (Suppl): S11–S17
Katusic ZS (2001) Vascular endothelial dysfunction: does tetrahydrobiopterin play a role? Am J Physiol Heart Circ Physiol 281: H981–H986
Elesber AA et al. (2006) Coronary endothelial dysfunction is associated with erectile dysfunction and elevated asymmetric dimethylarginine in patients with early atherosclerosis. Eur Heart J 27: 824–831
Foresta C et al. (2005) Circulating endothelial progenitor cells in subjects with erectile dysfunction. Int J Impot Res 17: 288–290
Wierzbicki AS et al. (2006) Asymmetric dimethyl arginine levels correlate with cardiovascular risk factors in patients with erectile dysfunction. Atherosclerosis 185: 421–425
Grundy SM et al.; American Heart Association; National Heart, Lung, and Blood Institute (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112: 2735–2752
Rosen RC et al. (1999) Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 11: 319–326
Cappelleri JC et al. (1999) Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function. Urology 54: 346–351
Walczak MK et al. (2002) Prevalence of cardiovascular risk factors in erectile dysfunction. J Gend Specif Med 5: 19–24
Wei M et al. (1994) Total cholesterol and high density lipoprotein cholesterol as important predictors of erectile dysfunction. Am J Epidemiol 140: 930–937
Feldman HA et al. (1994) Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 151: 54–61
Feldman HA et al. (2000) Erectile dysfunction and coronary risk factors: prospective results from the Massachusetts male aging study. Prev Med 30: 328–338
Greenstein A et al. (1997) Does severity of ischemic coronary disease correlate with erectile function? Int J Impot Res 9: 123–126
Kloner RA et al. (2003) Erectile dysfunction in the cardiac patient: how common and should we treat? J Urol 170 (Suppl): S46–S50
Solomon H et al. (2003) Relation of erectile dysfunction to angiographic coronary artery disease. Am J Cardiol 91: 230–231
Montorsi F et al. (2003) Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease. Eur Urol 44: 360–364
Chiurlia E et al. (2005) Subclinical coronary artery atherosclerosis in patients with erectile dysfunction. J Am Coll Cardiol 46: 1503–1506
Jackson G et al. (2006) The second Princeton consensus on sexual dysfunction and cardiac risk: new guidelines for sexual medicine. J Sex Med 3: 28–36
Esposito K et al. (2005) High proportions of erectile dysfunction in men with the metabolic syndrome. Diabetes Care 28: 1201–1203
Giugliano F et al. (2004) Erectile dysfunction associates with endothelial dysfunction and raised proinflammatory cytokine levels in obese men. J Endocrinol Invest 27: 665–669
Kato M et al. (2000) Impairment of endothelium-dependent vasodilation of resistance vessels in patients with obstructive sleep apnea. Circulation 102: 2607–2610
Margel D et al. (2004) Severe, but not mild, obstructive sleep apnea syndrome is associated with erectile dysfunction. Urology 63: 545–549
De Angelis L et al. (2001) Erectile and endothelial dysfunction in Type II diabetes: a possible link. Diabetologia 44: 1155–1160
Thompson IM et al. (2005) Erectile dysfunction and subsequent cardiovascular disease. JAMA 294: 2996–3002
Uslu N et al. (2006) Left ventricular diastolic function and endothelial function in patients with erectile dysfunction. Am J Cardiol 97: 1785–1788
Kaya C et al. (2006) Is endothelial function impaired in erectile dysfunction patients? Int J Impot Res 18: 55–60
Gazzaruso C et al. (2004) Relationship between erectile dysfunction and silent myocardial ischemia in apparently uncomplicated type 2 diabetic patients. Circulation 110: 22–26
Kaiser DR et al. (2004) Impaired brachial artery endothelium-dependent and -independent vasodilation in men with erectile dysfunction and no other clinical cardiovascular disease. J Am Coll Cardiol 43: 179–184
Bocchio M et al. (2004) Endothelial cell activation in men with erectile dysfunction without cardiovascular risk factors and overt vascular damage. J Urol 171: 1601–1604
Stuckey BGA et al. (2006) Erectile dysfunction predicts generalized cardiovascular disease: evidence from a case-control study. Atherosclerosis [doi:10.1016/j.atherosclerosis.2006.08.043]
Montorsi P et al. (2005) The artery size hypothesis: a macrovascular link between erectile dysfunction and coronary artery disease. Am J Cardiol 96 (Suppl 2): 19M–23M
Bonetti PO et al. (2003) Statin effects beyond lipid lowering—are they clinically relevant? Eur Heart J 24: 225–248
Woodman RJ et al. (2005) Mechanisms, significance and treatment of vascular dysfunction in type 2 diabetes mellitus: focus on lipid-regulating therapy. Drugs 65: 31–74
Esposito K et al. (2004) Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA 291: 2978–2984
Esposito K et al. (2006) Mediterranean diet improves erectile function in subjects with the metabolic syndrome. Int J Impot Res 18: 405–410
Margel D et al. (2005) Predictors of erectile function improvement in obstructive sleep apnea patients with long-term CPAP treatment. Int J Impot Res 17: 186–190
Rizvi K et al. (2002) Do lipid-lowering drugs cause erectile dysfunction? A systematic review. Fam Pract 19: 95–98
Bruckert E et al. (1996) Men treated with hypolipidaemic drugs complain more frequently of erectile dysfunction. J Clin Pharm Ther 21: 89–94
Solomon H et al. (2006) Erectile dysfunction and statin treatment in high cardiovascular risk patients. Int J Clin Pract 60: 141–145
Pedersen TR and Faergeman O (1999) Simvastatin seems unlikely to cause impotence. BMJ 318: 192
Herrmann HC et al. (2006) Can atorvastatin improve the response to sildenafil in men with erectile dysfunction not initially responsive to sildenafil? Hypothesis and pilot trial results. J Sex Med 3: 303–308
Speel TG et al. (2005) Long-term effect of inhibition of the angiotensin-converting enzyme (ACE) on cavernosal perfusion in men with atherosclerotic erectile dysfunction: a pilot study. J Sex Med 2: 207–212
Keene LC and Davies PH (1999) Drug-related erectile dysfunction. Adverse Drug React Toxicol Rev 18: 5–24
Fogari R et al. (2001) Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study. Am J Hypertens 14: 27–31
Corbin JD (2004) Mechanisms of action of PDE5 inhibition in erectile dysfunction. Int J Impot Res 16 (Suppl 1): S4–S7
Jackson G et al. (1999) Effects of sildenafil citrate on human hemodynamics. Am J Cardiol 83: 13C–20C
Katz SD et al. (2000) Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. J Am Coll Cardiol 36: 845–851
Halcox JPJ et al. (2002) The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. J Am Coll Cardiol 40: 1232–1240
Ghofrani HA et al. (2004) Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary hypertension. J Am Coll Cardiol 43 (Suppl): S68–72S
Desouza C et al. (2002) Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes. Diabetes Care 25: 1336–1339
Rosano GMC et al. (2005) Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol 47: 214–220
Hryniewicz K et al. (2005) Inhibition of angiotensin-converting enzyme and phosphodiesterase type 5 improves endothelial function in heart failure. Clin Sci (Lond) 108: 331–338
Solomon H et al. (2006) Cardiovascular risk factors determine erectile and arterial function response to sildenafil. Am J Hypertens 19: 915–919
DeBusk R et al. (2000) Management of sexual dysfunction in patients with cardiovascular disease: recommendations of the Princeton Consensus Panel. Am J Cardiol 86: 175–181
DeBusk RF (2005) Erectile dysfunction therapy in special populations and applications: coronary artery disease. Am J Cardiol 96: 62M–66M
Mittleman MA et al. (2005) Evaluation of acute risk for myocardial infarction in men treated with sildenafil citrate. Am J Cardiol 96: 443–446
Chew KK et al. (2000) Erectile dysfunction, sildenafil and cardiovascular risk. Med J Aust 172: 279–283
Sweeney M and Siegel RL (2004) Potential cardiac applications of phosphodiesterase type-5 inhibitors. In Contemporary Cardiology: Heart Disease and Erectile Dysfunction, 207–237 (Ed Kloner RA) Totowa: Humana Press Inc.
Bocchio M et al. (2005) Intima-media thickening of common carotid arteries is a risk factor for severe erectile dysfunction in men with vascular risk factors but no clinical evidence of atherosclerosis. J Urol 173: 526–529
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Watts, G., Chew, KK. & Stuckey, B. The erectile–endothelial dysfunction nexus: new opportunities for cardiovascular risk prevention. Nat Rev Cardiol 4, 263–273 (2007). https://doi.org/10.1038/ncpcardio0861
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpcardio0861
This article is cited by
-
Erectile dysfunction in patients with plaque psoriasis: the relation of depression and cardiovascular factors
International Journal of Impotence Research (2016)
-
Energy restriction and exercise modulate angiopoietins and vascular endothelial growth factor expression in the cavernous tissue of high-fat diet-fed rats
Asian Journal of Andrology (2012)
-
Chronic treatment with long acting phosphodiesterase-5 inhibitor tadalafil alters proteomic changes associated with cytoskeletal rearrangement and redox regulation in Type 2 diabetic hearts
Basic Research in Cardiology (2012)
-
Increased expression of insulin-like growth factor-binding protein-3 is implicated in erectile dysfunction in two-kidney one-clip hypertensive rats after propranolol treatment
Asian Journal of Andrology (2011)
-
Stem and endothelial progenitor cells in erection biology
International Journal of Impotence Research (2008)